Mahmut ŞAHİN

Prof. Dr. Mahmut ŞAHİN

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Verified
Journal Article
Open access
MKMustafa Kılıçkap
Mustafa Kılıçkap
CBCem Barçın
Cem Barçın
HGHüseyin Göksülük
Hüseyin Göksülük
DKDoruk Karaaslan
Doruk Karaaslan
NÖNecla Özer
Necla Özer
MŞMahmut ŞAHİN
Mahmut ŞAHİN
Despite some improvement, HT is still an important public health problem in Turkey.

4 March 2021 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
OGOmer Gedikli
Omer Gedikli
STSamsun- Turkey
Samsun- Turkey
SAServet Altay
Servet Altay
SÜserkan ünlü
serkan ünlü
HCHuseyin Altug Cakmak
Huseyin Altug Cakmak
SPSeckin Pehlivanoglu
Seckin Pehlivanoglu
This study aimed to evaluate the safety of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) during daily clinical practice. This was a prospective study conducted between January 01, 2016, and April 01, 2017, in patients aged ≥18 years with a diagnosis of NVAF. We performed the study in 9 clinical centers from different regions of Turkey, and the mean follow-up period was 12+2 months. We investigated major and minor bleeding events of DOAC. A total of 1807 patients with NVAF were enrolled. The mean age of the patients was 73.6±10.2 years, CHA2DS2-VASc score was 3.6±1.4, and HAS-BLED score was 2±1.2. The most frequently prescribed DOAC was dabigatran 110 mg bid in 409 (22.6%) patients. The patients on apixaban 2.5 mg bid were older (p<0.001). Patients on rivaroxaban 15 mg od also had a higher prevalence of chronic renal failure, 46 (16.7%) patients. A total of 205 (11.4%) bleeding events were observed; among these, 34 (1.9%) patients had major bleeding and 171 (9.4%) patients had minor bleeding. The major and minor bleeding events were 2/273 (0.7%) and 30/273 (10.9%) in patients receiving dabigatran 150 mg bid, 13/409 (3%) and 44/409 (10.7%) in patients receiving dabigatran 110 mg bid, 4/385 (1%) and 42/385 (10.9%) in patients receiving rivaroxaban 20 mg od, 8/276 (2.9%) and 27/276 (9.7%) in patients receiving rivaroxaban 15 mg od, 3/308 (0.9%) and 14/308 (4.5%) in patients receiving apixaban 5 mg bid, 4/156 (2.5%) and 14/156 (9%) in patients receiving apixaban 2.5 mg bid, respectively. The total bleeding events were 17 (5.6%) in patients receiving apixaban 5 mg, less than those receiving other DOACs. On multivariate analyses, rivaroxaban 20 mg od (p=0.002), ATRIA and HAS-BLED scores, and peripheral artery disease were independent indicators of bleeding. The most frequent location of major bleeding was the gastrointestinal system (GIS) [17 (0.9%) patients], and the most frequent location of minor bleeding was the gingiva [45 (2.5%) patients]. This study showed that similar results as the previous real-life study; however, we had some different results, such as the GIS tract bleeding was more frequent in patients receiving dabigatran 110 mg bid. The major and intracranial bleeding events were similar for different DOACs; and among DOACs, only rivaroxaban 20 mg od was associated with a high risk of bleeding.

16 April 2021 in Medicina
Verified
Journal Article
Open access
PDF file
SYSerkan Yüksel
Serkan Yüksel
MÇMetin Çoksevim
Metin Çoksevim
MMmurat meric
murat meric
MŞMahmut ŞAHİN
Mahmut ŞAHİN
Background and Objectives: An inter-arm systolic blood pressure difference (IASBPD) is defined as a blood pressure (BP) disparity of ≥10 mmHg between arms. IASBPDs are associated with an increased risk of cardiovascular disease (CVD). Similarly, visceral fat accumulation (VFA) is clinically important because it is associated with higher cardiovascular disease risk. Accordingly, this study compared the body composition parameters of IASBPD individuals with individuals who did not express an IASBPD. Materials and Methods: The analysis included 104 patients. The blood pressures of all participants were measured simultaneously in both arms using automated oscillometric devices. Then patients were divided into two groups according to their IASBPD status: Group 1 (IASBPD− (<10 mmHg)); Group 2 (IASPPD+ (≥10 mmHg)). Body composition parameters were measured using bioelectrical impedance analysis. Results: In 42 (40%) patients, the simultaneously measured IASBPD was equal to or higher than 10 mmHg. The right brachial SBP was higher in 63% of patients. There were no differences between the groups in terms of demographic and clinical characteristics. Regarding the two groups’ body composition parameter differences, VFA was significantly higher in group 2 (p = 0.014). Conclusions: The IASBPD is known to be associated with an increased risk of cardiovascular events. Although the body mass indexes (BMIs) of the two groups were similar, VFA levels in those with a greater than 10 mmHg IASBPD were found to be significantly higher. This finding may explain the increased cardiovascular risk in this group.

1 January 2016 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Verified
Journal Article
Closed access
MŞMahmut ŞAHİN
Mahmut ŞAHİN
The rate of traffic accidents due to medical causes is unknown. Based on data from Canada and the United States, cardiovascular conditions account for less than 5% of commercial vehicle accidents. European data shows that about 0.1% of reportable road accidents maybe attributed to medical conditions, of which 10-25% is due to cardiac events. Driving guidelines and regulations in cardiovascular diseases are of importance, not only for protecting the health of the patients but also for protection of the community. Therefore, our aim as the Turkish Society of Cardiology is to provide a guide for cardiologists that addresses this important issue, and reports a consensus on medical standards for drivers with cardiovascular disorders.

31 March 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
MAMurat Akcay
Murat Akcay
MÇMetin Çoksevim
Metin Çoksevim
UYUfuk Yildirim
Ufuk Yildirim
OGOmer Gedikli
Omer Gedikli
OGOkan Gulel
Okan Gulel
MŞMahmut ŞAHİN
Mahmut ŞAHİN
Thrombotic coronary artery occlusions usually manifest as acute coronary syndrome with cardiogenic shock, acute pulmonary edema, cardiac arrest, fatal arrhythmias, or sudden cardiac death. Although it usually occurs based on atherosclerosis, ft can also occur without atherosclerosis. There is no predictor of coronary artery thrombosis clinically and no consensus regarding the optimal treatment. In the current literature, treatment options include emergency coronary artery bypass grafting, entrapment of thrombus in vessel wall with stent implantation, intracoronary thrombolysis, glycoprotein IIb/IIIa inhibitors, anticoagulation with heparin, and thrombus aspiration as reperfusion strategies. Here, we reviewed a new treatment strategy based on the literature, and a case series with successful results in hemodynamically stable patients with low-dose slow infusion tissue plasminogen activator (tPA) for thrombotic coronary artery occlusions that allow coronary flow was reported. Prospective randomized studies and common consensus are needed on low-dose, slow-infusion tissue plasminogen activator treatment regimen and optimal treatment management for thrombotic coronary artery occlusions.

1 May 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
FBFuatcan Balaban
Fuatcan Balaban
MÇMetin Çoksevim
Metin Çoksevim
SYSerkan Yüksel
Serkan Yüksel
MŞMahmut ŞAHİN
Mahmut ŞAHİN